Entrada Therapeutics (TRDA) Treasury Shares (2020 - 2021)

Entrada Therapeutics' Treasury Shares history runs 7 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• In Q1 2026, Treasury Shares rose 3.35% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (up 3.35% YoY), while the FY2025 annual figure was $438500.0, down 77.72% from the prior year.
• Treasury Shares for Q1 2026 stood at $2.8 million, up from $438500.0 in the prior quarter.
• The five-year high for Treasury Shares was $2.8 million in Q1 2026, with the low at $438500.0 in Q3 2024.
• The 5-year median for Treasury Shares is $1.2 million (2023), against an average of $1.3 million.
• The sharpest annual moves came in 2022 and 2024: Treasury Shares plunged 99.68% in 2022, then soared 198.8% in 2024.
• Entrada Therapeutics' Treasury Shares stood at $463964.0 in 2022, then jumped by 173.4% to $1.3 million in 2023, then surged by 55.18% to $2.0 million in 2024, then plunged by 77.72% to $438500.0 in 2025, then jumped by 535.59% to $2.8 million in 2026.
• Business Quant data shows TRDA's Treasury Shares at $2.8 million in Q1 2026, $438500.0 in Q4 2025, and $438500.0 in Q3 2025.